CG Oncology (CGON) has drawn fresh attention after updating timelines for topline data from key Phase 2 and Phase 3 bladder cancer trials, while also highlighting a cash runway that management expects will extend into 2029.

The recent update on expedited trial timelines and a cash runway into 2029 comes after a strong run in the shares, with the latest close at $58.8, a 90 day share price return of 42.13% and a 1 year total shareholder return of 134.26%. This suggests momentum has been building as investors reassess both progress and risk around the bladder cancer pipeline.

If this kind of biotech momentum has your attention, it could be a good time to scan 28 healthcare AI stocks and see which other health focused names are catching interest right now.

With shares up strongly and the stock trading at a roughly 37% discount to a US$80.43 analyst target, alongside an intrinsic discount of about 80%, is CG Oncology still mispriced or is the market already baking in future growth?

Price to Book of 6.6x: Is It Justified?

On Simply Wall St's numbers, CG Oncology trades at a P/B of 6.6x at the last close of $58.8, sitting between cheaper peers and more expensive close comparables.

P/B compares the market value of the company to the accounting value of its net assets. It is often used for early stage or unprofitable biotechs where earnings are not yet a reliable anchor.

For CG Oncology, the data suggests a mixed picture. The stock is described as good value against a peer group average P/B of 11.1x, yet expensive relative to the broader US Biotechs industry average of 2.7x. That gap hints that investors are putting a higher tag on its pipeline and trial progress than the typical biotech name, while still paying less than for some closer high priced peers.

Compared with the industry, the 6.6x P/B sits at more than double the 2.7x sector average. This is a strong premium and suggests expectations that differ from the wider group. There is no fair ratio estimate available, so there is no statistical anchor for where this multiple could settle based on historical relationships. This leaves the current level dependent on how the story around trials and future cash generation develops.

Result: Price-to-book of 6.6x (ABOUT RIGHT)

However, results from ongoing trials and the current net loss of $160.995m could quickly challenge the optimism embedded in today’s price to book ratio and discount to targets.

Another View: What The DCF Model Says

While the 6.6x P/B ratio points to a middle ground between cheaper and pricier peers, our DCF model presents a very different picture. On these cash flow assumptions, CG Oncology at $58.8 is trading at roughly an 80% discount to an estimated fair value of $292.05.

That gap indicates the market price and the DCF view are far apart, which can signal either a potential opportunity or a sign that the cash flow assumptions are too optimistic. For you as an investor, the central question is which perspective you place more weight on: the balance sheet multiple or the long range cash flow model?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CG Oncology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Curious whether the optimism in this story outweighs the risks or the other way around? Take a moment to review the numbers yourself and decide how you feel about CG Oncology, then round out your view by checking 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If CG Oncology has sparked your interest, do not stop here. The market is full of other opportunities that could suit your style and risk comfort.

• Target stability first by checking out 76 resilient stocks with low risk scores that aim to help keep portfolio shocks in check while you focus on the long game.
• Hunt for value by reviewing screener containing 24 high quality undiscovered gems where strong fundamentals may not yet be fully appreciated by the wider market.
• Strengthen your core holdings by focusing on companies from our solid balance sheet and fundamentals stocks screener (41 results) that put financial resilience front and center.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.